CODX Quote, Financials, Valuation and Earnings

Celldex Therapeutics, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -67204.13%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Celldex Therapeutics, Inc.'s return on equity of -40.04%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 2822.08%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $54.33 which suggests that it could grow by 74.99%. Given that Co-Diagnostics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Celldex Therapeutics, Inc..

Co-Diagnostics, Inc. has a beta of 1.420, which suggesting that the stock is 41.965% more volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.194, suggesting its more volatile than the S&P 500 by 19.434%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are larger than Celldex Therapeutics, Inc. quarterly revenues of $121K. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Celldex Therapeutics, Inc.'s net income of -$81.3M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 33.61x versus 1,334.01x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Precipio, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -1.17%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Precipio, Inc.'s return on equity of -10.15%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 2822.08%. On the other hand Precipio, Inc. has an analysts' consensus of -- which suggests that it could fall by -25.2%. Given that Co-Diagnostics, Inc. has higher upside potential than Precipio, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Precipio, Inc..

Co-Diagnostics, Inc. has a beta of 1.420, which suggesting that the stock is 41.965% more volatile than S&P 500. In comparison Precipio, Inc. has a beta of 1.194, suggesting its more volatile than the S&P 500 by 19.441%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precipio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Precipio, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Precipio, Inc. quarterly revenues of $6.8M. Co-Diagnostics, Inc.'s net income of -$5.9M is lower than Precipio, Inc.'s net income of -$79K. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Precipio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 33.61x versus 1.72x for Precipio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -417.92%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Plus Therapeutics, Inc.'s return on equity of --.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 2822.08%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Co-Diagnostics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Co-Diagnostics, Inc..

Co-Diagnostics, Inc. has a beta of 1.420, which suggesting that the stock is 41.965% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Co-Diagnostics, Inc.'s net income of -$5.9M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 33.61x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sera Prognostics, Inc. has a net margin of -4048.69% compared to Co-Diagnostics, Inc.'s net margin of -78810%. Co-Diagnostics, Inc.'s return on equity of -65.15% beat Sera Prognostics, Inc.'s return on equity of -41.1%.

Co-Diagnostics, Inc. has a consensus price target of $1.50, signalling upside risk potential of 2822.08%. On the other hand Sera Prognostics, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 148.76%. Given that Co-Diagnostics, Inc. has higher upside potential than Sera Prognostics, Inc., analysts believe Co-Diagnostics, Inc. is more attractive than Sera Prognostics, Inc..

Co-Diagnostics, Inc. has a beta of 1.420, which suggesting that the stock is 41.965% more volatile than S&P 500. In comparison Sera Prognostics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Co-Diagnostics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sera Prognostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Co-Diagnostics, Inc. pays -- of its earnings as a dividend. Sera Prognostics, Inc. pays out -- of its earnings as a dividend.

Co-Diagnostics, Inc. quarterly revenues are $145.4K, which are larger than Sera Prognostics, Inc. quarterly revenues of $10K. Co-Diagnostics, Inc.'s net income of -$5.9M is higher than Sera Prognostics, Inc.'s net income of -$7.9M. Notably, Co-Diagnostics, Inc.'s price-to-earnings ratio is -- while Sera Prognostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Co-Diagnostics, Inc. is 33.61x versus 1,142.08x for Sera Prognostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.